Preclinical Toxicity of AZD7969:Effects of GSK3β Inhibition in Adult Stem Cells

Toxicologic Pathology

Volumn 43, Issue 3, 2015, Pages 384-399

  Hall, A P ^a   Escott, K J ^b   Sanganee, H ^b   Hickling, K C ^a  

^a Drug Safety and Metabolism Astra Zeneca   (United Kingdom)

^b Scientific Partnering Alliances   (United Kingdom)

Author keywords

AZD7969; glycogen synthase kinase 3 ; GSK3b; safety assessment; stem cell

Indexed keywords

AZD 7969; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; IRON; UNCLASSIFIED DRUG; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3;

ADULT STEM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HEMOSIDEROSIS; INVESTIGATIVE PROCEDURES; IRON STORAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD CELL COUNT; BODY WEIGHT; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; EATING; LIVER; METABOLISM; PATHOLOGY; STEM CELL;

CANIS FAMILIARIS; RATTUS;

ANIMALS; BLOOD CELL COUNT; BODY WEIGHT; CELL PROLIFERATION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; ENZYME INHIBITORS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; INTESTINE, SMALL; IRON; LIVER; MALE; RATS; STEM CELLS;

EID: 84930829275     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623314544468     Document Type: Article

References (58)

1. Cadigan K. M. Liu Y. I. (2006). Wnt signaling: Complexity at the surface. J Cell Sci 119, 395–402.
2. Chen R. H. Ding W. V. McCormick F. (2000). Wnt signaling to beta-catenin involves two interactive components. Glycogen synthase kinase-3beta inhibition and activation of protein kinase C. J Biol Chem 275, 17894–99.
3. Clement-Lacroix P. Ai M. Morvan F. Roman-Roman S. Vayssiere B. Belleville C. Estrera K. Warman M. L. Baron R. Rawadi G. (2005). Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA 102, 17406–11.
4. Clevers H. (2006). Wnt/beta-catenin signaling in development and disease. Cell 127, 469–80.
5. Cline G. W. Johnson K. Regittnig W. Perret P. Tozzo E. Xiao L. Damico C. Shulman G. I. (2002). Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes 51, 2903–10.
6. Cobas M. Wilson A. Ernst B. Mancini S. J. MacDonald H. R. Kemler R. Radtke F. (2004). Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. J Exp Med 199, 221–9.
7. Eldar-Finkelman H. (2002). Glycogen synthase kinase 3: An emerging therapeutic target. Trends Mol Med 8, 126–32.
8. Embi N. Rylatt D. B. Cohen P. (1980). Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107, 519–27.
9. Ernest Dodd M. Ristich V. L. Ray S. Lober R. M. Bollag W. B. (2005). Regulation of protein kinase D during differentiation and proliferation of primary mouse keratinocytes. J Invest Dermatol 125, 294–306.
10. Esfandiari F. Fathi A. Gorabi H. Kiani S. Nemati S. Baharvand H. (2012). Glycogen synthase kinase-3 inhibition promotes proliferation and neuronal differentiation of human-induced pluripotent stem cell-derived neural progenitors. Stem Cells Dev 21, 3233–43.
11. Fletcher A. M. Bregman C. L. Woicke J. Salcedo T. W. Zidell R. H. Janke H. E. Fang H. Janusz W. J. Schulze G. E. Mense M. G. (2010). Incisor degeneration in rats induced by vascular endothelial growth factor/fibroblast growth factor receptor tyrosine kinase inhibition. Toxicol Pathol 38, 267–79.
12. Frame S. Cohen P. Biondi R. M. (2001). A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7, 1321–7.
13. Galli C. Piemontese M. Lumetti S. Manfredi E. Macaluso G. M. Passeri G. (2012). GSK3b-inhibitor lithium chloride enhances activation of Wnt canonical signaling and osteoblast differentiation on hydrophilic titanium surfaces. Clin Oral Implants Res 24, 921–27.
14. Gambardella A. Nagaraju C. K. O'shea P. J. Mohanty S. T. Kottam L. Pilling J. Sullivan M. Djerbi M. Koopmann W. Croucher P. I. Bellantuono I. (2011). Glycogen synthase kinase-3α/β inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage. J Bone Miner Res 26, 811–21.
15. Gilmour P. S. O’Shea P. J. Fagura M. Pilling J. E. Sanganee H. Wada H. Courtney P. F. Kavanagh S. Hall P. A. Escott K. J. (2013). Human stem cell osteoblastogenesis mediated by novel glycogen synthase kinase 3 inhibitors induces bone formation and a unique bone turnover biomarker profile in rats. Toxicol Appl Pharmacol 272, 399–407.
16. Gong Y. Slee R. B. Fukai N. Rawadi G. Roman-Roman S. Reginato A. M. Wang H. Cundy T. Glorieux F. H. Lev D. Zacharin M. Oexle K. Marcelino J. Suwairi W. Heeger S. Sabatakos G. Apte S. Adkins W. N. Allgrove J. Arslan-Kirchner M. Batch J. A. Beighton P. Black G. C. Boles R. G. Boon L. M. Borrone C. Brunner H. G. Carle G. F. Dallapiccola B. De Paepe A. Floege B. Halfhide M. L. Hall B. Hennekam R. C. Hirose T. Jans A. Juppner H. Kim C. A. Keppler-Noreuil K. Kohlschuetter A. LaCombe D. Lambert M. Lemyre E. Letteboer T. Peltonen L. Ramesar R. S. Romanengo M. Somer H. Steichen-Gersdorf E. Steinmann B. Sullivan B. Superti-Furga A. Swoboda W. van den Boogaard M. J. Van Hul W. Vikkula M. Votruba M. Zabel B. Garcia T. Baron R. Olsen B. R. Warman M. L. Osteoporosis-Pseudoglioma Syndrome Collaborative Group. (2001). LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513–23.
17. Hailemariam K. Iwasaki K. Huang B. W. Sakamoto K. Tsuji Y. (2010). Transcriptional regulation of ferritin and antioxidant genes by HIPK2 under genotoxic stress. J Cell Sci 123, 3863–71.
18. Hall A. P. Davies W. Stamp K. Clamp I. Bigley A. (2013). Comparison of computerized image analysis with traditional semiquantitative scoring of Perls' Prussian Blue stained hepatic iron deposition. Toxicol Pathol 41, 992–1000.
19. Hall A. P. Westwood F. R. Wadsworth P. F. (2006). Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate. Toxicol Pathol 34, 131–47.
20. He T. C. Chan T. A. Vogelstein B. Kinzler K. W. (1999). PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99, 335–45.
21. He T. C. Sparks A. B. Rago C. Hermeking H. Zawel L. da Costa L. T. Morin P. J. Vogelstein B. Kinzler K. W. (1998). Identification of c-MYC as a target of the APC pathway. Science 281, 1509–12.
22. Hoeflich K. P. Luo J. Rubie E. A. Tsao M. S. Jin O. Woodgett J. R. (2000). Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406, 86–90.
23. Hofbauer L. C. Maisch B. Schaefer J. R. (2002). High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 347, 943,4; author reply 943–4.
24. Huelsken J. Vogel R. Erdmann B. Cotsarelis G. Birchmeier W. (2001). beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell 105, 533–45.
25. R.S., Jope, G.G.W., Johnson, The glamour and gloom of glycogen synthase kinase-3, Trends Biochem Sci, (2004), 29, 95-102
26. Kang T. Wei Y. Honaker Y. Yamaguchi H. Appella E. Hung M. C. Piwnica-Worms H. (2008). GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 13, 36–47.
27. Kannoji A. Phukan S. Sudher Babu V. Balaji V. N. (2008). GSK3beta: A master switch and a promising target. Expert Opin Ther Targets 12, 1443–55.
28. Kato M. Patel M. S. Levasseur R. Lobov I. Chang B. H. Glass D. A. 2nd Hartmann C. Li L. Hwang T. H. Brayton C. F. Lang R. A. Karsenty G. Chan L. (2002). Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157, 303–14.
29. Kavukcu S. Soylu A. Turkmen M. (2002). The clinical value of urinary N-acetyl-beta-D-glucosaminidase levels in childhood age group. Acta Med Okayama 56, 7–11.
30. Kim W. Y. Snider W. D. (2011). Functions of GSK-3 Signaling in development of the nervous system. Front Mol Neurosci 17, 4: 44.
31. Kinzler K. W. Vogelstein B. (1996). Lessons from hereditary colorectal cancer. Cell 87, 159–70.
32. Korinek V. Barker N. Moerer P. van Donselaar E. Huls G. Peters P. J. Clevers H. (1998). Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4. Nat Genet 19, 379–83.
33. Kugimiya F. Kawaguchi H. Ohba S. Kawamura N. Hirata M. Chikuda H. Azuma Y. Woodgett J. R. Nakamura K. Chung U. I. (2007). GSK-3beta controls osteogenesis through regulating Runx2 activity. PLoS One 2, e837.
34. Kuhnert F. Davis C. R. Wang H. T. Chu P. Lee M. Yuan J. Nusse R. Kuo C. J. (2004). Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc Natl Acad Sci U S A 101, 266–71.
35. Kulkarni N. H. Onyia J. E. Zeng Q. Tian X. Liu M. Halladay D. L. Frolik C. A. Engler T. Wei T. Kriauciunas A. Martin T. J. Sato M. Bryant H. U. Ma Y. L. (2006). Orally bioavailable GSK-3alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Miner Res 21, 910–20.
36. Lee S. H. Yoon J. Shin S. H. Zahoor M. Kim H. J. Park P. J. Park W. S. Min do S. Kim H. Y. Choi K. Y. (2012). Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells. PLoS One 7, e34152.
37. Little R. D. Carulli J. P. Del Mastro R. G. Dupuis J. Osborne M. Folz C. Manning S. P. Swain P. M. Zhao S. C. Eustace B. Lappe M. M. Spitzer L. Zweier S. Braunschweiger K. Benchekroun Y. Hu X. Adair R. Chee L. FitzGerald M. G. Tulig C. Caruso A. Tzellas N. Bawa A. Franklin B. McGuire S. Nogues X. Gong G. Allen K. M. Anisowicz A. Morales A. J. Lomedico P. T. Recker S. M. Van Eerdewegh P. Recker R. R. Johnson M. L. (2002). A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70, 11–9.
38. P.A., Lochhead, M., Coghlan, S.S.J., Rice, C., Sutherland, Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression, Diabetes, (2001), 50, 937-946
39. Marsell R. Sisask G. Nilsson Y. Sundgren-Andersson A. K. Andersson U. Larsson S. Nilsson O. Ljunggren O. Jonsson K. B. (2012). GSK-3 inhibition by an orally active small molecule increases bone mass in rats. Bone 50, 619–27.
40. McLaren G. D. Muir W. A. Kellermeyer R. W. (1983). Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. Crit Rev Clin Lab Sci. 19, 205–66.
41. Mishra R. (2010). Glycogen synthase kinase 3 beta: Can it be a target for oral cancer. Molecular Cancer 9 JUN 11 2010. Article No.:144.
42. Nemeth E. Ganz T. (2009). The role of hepcidin in iron metabolism. Acta Haematol 122, 78–86.
43. Nikoulina S. E. Ciaraldi T. P. Mudaliar S. Carter L. Johnson K. Henry R. R. (2002). Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes 51, 2190–98.
44. Patel S. Doble B. Woodgett J. R. (2004). Glycogen synthase kinase-3 in insulin and Wnt signalling: A double-edged sword? Biochem Soc Trans 32, 803–8.
45. Patyna S. Arrigoni C. Terron A. Kim T. W. Heward J. K. Vonderfecht S. L. Denlinger R. Turnquist S. E. Evering W. (2008). Nonclinical safety evaluation of sunitinib: A potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors. Toxicol Pathol 36, 905–16.
46. Rahmani Z. Lopes C. Rachidi M. Delabar J. M. (1998). Expression of the mnb (dyrk) protein in adult and embryonic mouse tissues. Biochem Biophys Res Commun 253, 514–18.
47. Rubinfeld B. Albert I. Porfiri E. Fiol C. Munemitsu S. Polakis P. (1996). Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science 272, 1023–26.
48. Satoh H. Uesugi Y. Kawabata T. Mori K. Fujii F. Kashimoto Y. Kajimura T. Furuhama K. (2001). Morphological classification of dental lesions induced by various antitumor drugs in mice. Toxicol Pathol 29, 292–9.
49. Si W. Kang Q. Luu H. H. Park J. K. Luo Q. Song W. X. Jiang W. Luo X. Li X. Yin H. Montag A. G. Haydon R. C. He T. C. (2006). CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol 26, 2955–64.
50. Sreehari S. Naik D. R. Eapen M. (2011). Osteopetrosis: A rare cause of anemia. Hematol Rep 3, e1.
51. Stambolic V. Woodgett J. R. (1994). Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J 303, 701–4.
52. Tang Q. L. Xie X. B. Wang J. Chen Q. Han A. J. Zou C. Y. Yin J. Q. Liu D. W. Liang Y. Zhao Z. Q. Yong B. C. Zhang R. H. Feng Q. S. Deng W. G. Zhu X. F. Zhou B. P. Zeng Y. X. Shen J. N. Kang T. (2012). Glycogen synthase kinase-3beta, NF-kappaB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst 104, 749–63.
53. Tanwar P. S. Kaneko-Tarui T. Zhang L. Rani P. Taketo M. M. Teixeira J. (2010). Constitutive WNT/beta-catenin signaling in murine Sertoli cells disrupts their differentiation and ability to support spermatogenesis. Biol Reprod 82, 422–32.
54. Tetsu O. McCormick F. (1999). Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422–6.
55. S. C. S. S. Chaube S. K. Singh S. P. (2003). Subchronic supplementation of lithium carbonate induces reproductive system toxicity in male rat. Reprod Toxicol 17, 683–90.
56. Van Den Berg D. J. Sharma A. K. Bruno E. Hoffman R. (1998). Role of members of the Wnt gene family in human hematopoiesis. Blood 92, 3189–202.
57. Wang H. L. Hart J. Fan L. Mustafi R. Bissonnette M. (2011). Upregulation of glycogen synthase kinase 3beta in human colorectal adenocarcinomas correlates with accumulation of CTNNB1. Clin Colorectal Cancer 10, 30–6.
58. Yoshida K. (2008). Role for DYRK family kinases on regulation of apoptosis. Biochem Pharmacol 76, 1389–94.